2000;85(6):829 -38. 74. Lepone LM, Donahue RN, Grenga I, Metenou S, Richards J, Heery CR, et al. Analysis of 123 peripheral human immune cell subsets: defining differences with age and between healthy donors and cancer patients not detec ted in analysis of standard immune cell types. J Circ Biomark. In press. 75. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate leve ls of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148 -59. 76. Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade -Lauraine E, Jakobsen A, et al. Re: New guidelines to evaluate the response to t reatment in solid tumors (ovarian cancer). J Natl Cancer Inst. 2004;96(6):487 -8. 77. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen -independent prostat e cancer: recommendations from the Prostate -Specific Antigen Working Group. J Clin Oncol. 1999;17(11):3461 -7. Abbreviated Title: Ad5 -based combination vaccines Version Date: 05.16.2018 73 78. Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade -Lauraine E, Parmar MK, et al. Re: new guidelines to evaluate the response to treatm ent in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst. 2000;92(18):1534 -5. 79. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer (Oxford, England : 1990). 2009;45(2):228 -47. Abbreviated Title: Ad5 -based combination vaccines Version Date: 05.16.2018 74 13 APPENDICES 13.1 APPENDIX A: PERFORMANCE STATUS CRITERIA ECOG Performance Status Scale Karnofsky Performance Scale Grade Descriptions Percent Description 0 Normal activity. Fully active, able to carry on all pre -disease performance without restriction. 100 Normal, no complaints, no evidence of disease. 90 Able to carry on normal activity; minor signs or symptoms of disease. 1 Symptoms, but ambulatory. Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work). 80 Normal activity with effort; some signs or symptoms of disease. 70 Cares for self, unable to carry on normal activity or to do active work. 2 In bed <50% of the time. Ambulatory and capable of all self-care, but unable to carry out any work activities. Up and about more than 50% of waking hours. 60 Requires occasional assistance, but is able to care for most of his/her needs. 50 Requires considerable assistance and frequent medical care. 3 In bed >50% of the time. Capable of only limited self -care, confined to bed or chair more than 50% of waking hours. 40 Disabled, requires special care and assistance. 30 Severely disabled, hospitalization indicated. Death not imminent. 4 100% bedridden. Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 20 Very sick, hospitalization indicated. Death not imminent. 10 Moribund, fatal processes progressing rapidly. 5 Dead.